Complete Genomics Stock Hits New 52-Week Low (GNOM)

NEW YORK ( TheStreet) -- Complete Genomics (Nasdaq: GNOM) hit a new 52-week low Wednesday as it is currently trading at $2.15, below its previous 52-week low of $2.21 with 211,067 shares traded as of 10:10 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Complete Genomics has a market cap of $90.8 million and is part of the health care sector and drugs industry. Shares are down 23.5% year to date as of the close of trading on Tuesday.

Complete Genomics, Inc., a life sciences company, develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.

TheStreet Ratings rates Complete Genomics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full Complete Genomics Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued